Chapter 4891

The poison pill plan will effectively reduce the shareholding ratio of hostile acquirers.

Take Amgen Pharmaceuticals as an example. Their total share capital is only about 535 million shares. The five major capital groups have acquired more than 50 million shares, either openly or secretly, and their shareholding ratio is about to exceed 10%.

However, if Amgen Pharmaceuticals implements the poison pill plan and issues a large number of new shares to increase the total share capital to more than 1.07 billion shares, it means that the shareholding ratio of the five major capital groups will drop to less than 5%.

Of course, there are many detailed restrictions on the actual poison pill plan, including the preferred purchaser of the additional shares, the price of the additional shares, the number of additional shares, etc.

But in general, the poison pill plan is more beneficial to the original shareholders and very unfavorable to the hostile acquirers.

Because of the existence of the poison pill plan, a large number of acquisitions have been blocked.

For example, when Shanda Games of Xiaguo tried to acquire Xinlang Games, Xinlang Games blocked it with a poison pill plan, which resulted in the failure of Shanda Games' acquisition plan.

Poison pill plans are very common in the Bald Eagle Capital Market, and more than 4,000 companies in the Bald Eagle Stock Market have set up poison pill plan clauses.

Amgen Pharmaceuticals also has a poison pill plan to avoid losing its equity or even being taken over by others.

So at this moment, when facing an unknown acquisition, Hiram would ask Williams whether to start a poison pill plan to prevent possible hostile acquisitions.

Faced with Hiram's proposal, Williams did not immediately agree. He responded, "There is no need to start the poison pill plan for the time being. Let's first investigate who is acquiring our stocks."

Hiram hesitated for a few seconds, but still asked, "Is it possible that it is from Xiaguo?"

Hiram meant whether it was possible that Anxin Life Sciences Group was behind the acquisition of Amgen Pharmaceuticals.

Amgen Pharmaceuticals and Anxin Life Sciences Group are now working closely together to conduct in-depth research and development around rapamycin.

If Anxin Life Sciences Group has achieved certain research and development results, it will have the motivation to acquire Amgen Pharmaceuticals' shares in advance.

After all, under the premise of having research and development results, as long as the shares of Amgen Pharmaceuticals are acquired, whether it is to gain greater voice in the future or to cash out directly in the stock market, huge benefits can be obtained.

Such speculation is reasonable!

After all, Anxin Life Sciences Group can indeed obtain huge benefits through such operations.

However, Williams directly denied the response, "It is impossible that Anxin Life is behind the scenes."

Hiram was puzzled, "Why?"

"Hiram, you have been in charge of marketing and don't know about our cooperation with Anxin Life." Williams said with a sigh.

"This time IOur cooperation with Anxin Life seems to be equal on the surface. We each hold 50% of the profit rights of the rapamycin project, but in fact, we are not equal to Anxin Life at all. "Williams added.

"In the cooperation with rapamycin, the core research is handled by Anxin Life, and we are only responsible for handling some trivial matters and conducting some data analysis." Williams added.

Speaking of this, Williams sighed again, "We have no access to the most core experimental operations, related data, and even research results. ”

Williams is actually very clear about the unequal cooperation between them and Anxin Life Sciences Group, but even if it is unequal, they have to cooperate, after all, if they cooperate, they will have a 50% profit right on the surface.

Please give me flowers

If you don’t cooperate?

It is estimated that Anxin Life Sciences Group can also start a new business, catch up with the research progress of rapamycin, and add thousand-year-old astragalus to the research.

Amgen Pharmaceutical Company does not have thousand-year-old astragalus to invest in research!

Hiram thought for a while before responding, "If Anxin Life is not behind the scenes, then there are two other suspects."

Hiram added, "The first suspect is other pharmaceutical companies. They probably don’t know the details of our cooperation with Anxin Life, so they hope to acquire us and get involved in the rapamycin cooperation project. ”

As the senior vice president of marketing at Amgen Pharmaceuticals, Hiram didn’t know the details of their company’s cooperation with Anxin Life on rapamycin, let alone the outside world?

So it was natural for Hiram to suspect that other pharmaceutical companies were behind the scenes.

“The second suspect is the vampires on Wall Street. They know about our cooperation with Anxin Life on rapamycin, and they also know that Anxin Life has the holy medicine. They should have smelled the core secrets.” Hiram added.

There are many names for the thousand-year-old astragalus in Bald Eagle, including holy medicine, miracle, divine grace, miracle holy relic, etc.

“Your analysis makes sense, I also suspect them, but there is no need to start the poison pill plan at present. "Williams does suspect other peers or vampires on Wall Street.

But there is no clear evidence that the two are behind the scenes, so Williams has no intention of launching a poison pill plan for the time being.

After all, launching a poison pill plan can indeed snipe hostile acquirers, but it is not a good thing for Amgen Pharmaceuticals..